Quick Takeaways
- Paul Edward Walker has 13 issuer positions tracked on this page.
- Estimated disclosed ownership value: $363,904,182.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Paul Edward Walker
- Location
- Menlo Park, CA
- Summary
- The estimated net worth of Paul Edward Walker is at least $363,904,182 dollars as of 12 Mar 2026. Paul Edward Walker is the 10%+ Owner of Monte Rosa Therapeutics, Inc. and owns shares of Monte Rosa Therapeutics, Inc. (GLUE) stock worth about $146.15M. Paul Edward Walker is the 10%+ Owner of Savara Inc and owns shares of Savara Inc (SVRA) stock worth about $108.9M. Paul Edward Walker is the 10%+ Owner of MBX Biosciences, Inc. and owns shares of MBX Biosciences, Inc. (MBX) stock worth about $38.64M. Paul Edward Walker is the 10%+ Owner of SpyGlass Pharma, Inc. and owns shares of SpyGlass Pharma, Inc. (SGP) stock worth about $37.77M. Paul Edward Walker is the 10%+ Owner of Trevi Therapeutics, Inc. and owns shares of Trevi Therapeutics, Inc. (TRVI) stock worth about $16.81M. Paul Edward Walker is the 10%+ Owner of Korro Bio, Inc. and owns shares of Korro Bio, Inc. (KRRO) stock worth about $14.42M. Paul Edward Walker is the 10%+ Owner of Metacrine, Inc. and owns shares of Metacrine, Inc. stock worth about $1.2M. Paul Edward Walker is the 10%+ Owner of Mirum Pharmaceuticals, Inc. and owns shares of Mirum Pharmaceuticals, Inc. (MIRM) stock worth about $3.2K.
- Signature
- /s/ Zachary Bambach, attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Paul Edward Walker and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Monte Rosa Therapeutics, Inc. ($146,153,662).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Paul Edward Walker
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | 10%+ Owner | $146,153,662 | 28 Jun 2021 | ||
| SVRA | Savara Inc | 10%+ Owner | $108,897,125 | 17 Jul 2023 | ||
| MBX | MBX Biosciences, Inc. | 10%+ Owner | $38,638,855 | 16 Sep 2024 | ||
| SGP | SpyGlass Pharma, Inc. | 10%+ Owner | $37,772,629 | 09 Feb 2026 | ||
| TRVI | Trevi Therapeutics, Inc. | 10%+ Owner | $16,814,393 | 31 Dec 2025 | ||
| KRRO | Korro Bio, Inc. | 10%+ Owner | $14,419,591 | +$2,300,881 | +19% | 10 Mar 2026 |
| MTCR | Metacrine, Inc. | 10%+ Owner | $1,204,731 | 10 Dec 2021 | ||
| MIRM | Mirum Pharmaceuticals, Inc. | 10%+ Owner | $3,196 | 13 Jun 2023 | ||
| ALLK | Allakos Inc. | Director | $0 | 15 May 2025 | ||
| NEUE | NeueHealth, Inc. | Director, 10%+ Owner | $0 | -$26,426 | -100% | 02 Oct 2025 |
| AKUS | Akouos, Inc. | 10%+ Owner | 30 Nov 2022 | |||
| GNCA | GENOCEA BIOSCIENCES, INC. | 10%+ Owner | 24 May 2022 | |||
| TRIL | Trillium Therapeutics Inc. | Director | 17 Nov 2021 |
Insider Transactions Reported by Paul Edward Walker:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.